NCT00695318View on ClinicalTrials.gov

Fluocinolone Acetonide Intravitreal Inserts in Geographic Atrophy

PHASE2TerminatedINTERVENTIONAL

Enrollment

17

Participants

Timeline

Start Date

December 31, 2008

Primary Completion Date

October 31, 2013

Conditions

Age-Related Macular Degeneration

Interventions

DRUG

Fluocinolone Acetonide

0.2 µg/Day in study eye + Sham in fellow eye

DRUG

Fluocinolone Acetonide

0.5 µg/Day in study eye +Sham in fellow eye

Trial Locations (1)

Unknown

Kresge Eye Institute, Detroit

Sponsors

Lead Sponsor

Alimera Sciences

All Listed Sponsors

lead

Alimera Sciences

INDUSTRY